TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Clin Cardiol. 2013 Mar;36(3):139-45. doi: 10.1002/clc.22089. Epub 2013 Feb 3.
The potential of iron to generate reactive oxygen species has motivated a long-standing interest in whether excess iron is causally linked to atherosclerotic heart disease. Circulating catalytic iron ("free" iron) is that which is not bound to transferrin or ferritin and is available to generate reactive oxygen species that may have deleterious vascular effects.
We hypothesized that increased levels of catalytic iron would be associated with increased cardiovascular events.
We investigated the association of catalytic iron with clinical outcomes in 1701 patients with unstable angina, non-ST-segment elevation myocardial infarction (MI), or ST-segment elevation MI who were followed for a median of 10 months. All endpoints were adjudicated by a blinded Clinical End Points Committee.
The median catalytic iron level was significantly higher in those who died, 0.45 µmol/L (0.37, 0.57), compared with survivors, 0.37µmol/L (0.31, 0.46; P = 0.016). Catalytic iron was associated with a stepwise increased risk of death, with the highest quartile at an almost 4-fold risk compared with baseline (hazard ratio: 3.94, P = 0.035), which persisted after adjustment for age, diabetes, prior MI, prior congestive heart failure, ST-segment deviation, creatinine clearance, B-type natriuretic peptide, smoking, and Killip class (adjusted hazard ratio: 3.97, P = 0.036). There was no association between catalytic iron and risk of MI, recurrent ischemia, heart failure, or bleeding.
Increasing catalytic iron levels were associated with increased all-cause mortality. Although our findings suggest that catalytic iron is not likely to add to available tools as a routine biomarker for risk stratification of recurrent ischemic events, its association with mortality is intriguing and leaves open the question of whether cardiovascular therapeutics aimed at catalytic iron may be useful. The TIMI Study Group has received research grant support from the Muljibhai Patel Society for Research in Nephro-Urology.
铁产生活性氧的潜力促使人们长期关注过量铁是否与动脉粥样硬化性心脏病有因果关系。循环中的催化铁(“游离”铁)是指未与转铁蛋白或铁蛋白结合且可产生活性氧的铁,这些活性氧可能对血管有有害影响。
我们假设增加的催化铁水平与心血管事件的增加有关。
我们研究了 1701 例不稳定型心绞痛、非 ST 段抬高型心肌梗死(MI)或 ST 段抬高型 MI 患者的催化铁与临床结局的相关性,这些患者的中位随访时间为 10 个月。所有终点均由盲法临床终点委员会裁定。
死亡患者的中位催化铁水平明显较高,为 0.45µmol/L(0.37,0.57),而幸存者为 0.37µmol/L(0.31,0.46;P=0.016)。催化铁与死亡风险呈逐步增加的关系,最高四分位组的死亡风险几乎是基线的 4 倍(危险比:3.94,P=0.035),调整年龄、糖尿病、既往 MI、既往充血性心力衰竭、ST 段偏移、肌酐清除率、B 型利钠肽、吸烟和 Killip 分级后仍然如此(校正危险比:3.97,P=0.036)。催化铁与 MI、复发性缺血、心力衰竭或出血风险之间无关联。
催化铁水平升高与全因死亡率增加有关。尽管我们的研究结果表明,催化铁不太可能作为复发性缺血事件风险分层的常规生物标志物增加现有工具,但它与死亡率的关联令人关注,这就提出了一个问题,即针对催化铁的心血管治疗是否可能有用。TIMI 研究小组已从 Muljibhai Patel 肾脏病和泌尿科研究协会获得研究资助。